Takeda Rozerem Clinical Significance Debated In FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency revieweres questioned the insomnia drug’s failure to meet subjective secondary endpoints despite efficacy on objective sleep measurements.
You may also be interested in...
Ambien CR Gets FDA Approval; Launch Expected In Mid-September
Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.